Report to Society 2026 – Expert perspectives on the impact of the biopharmaceutical sector

Nieuws
Sector
Maatschappelijke impact

What impact does biopharmaceutical innovation have on patients, healthcare, society or even the economy? To look beyond the figures, we have invited several experts to share their views on innovation and the tangible impact of the biopharmaceutical sector. Discover their insights, convictions and perspectives through a series of video interviews for our Report to Society 2026.

In conversation with Prof Vincent van Pesch (p.21)

Clinical trials are an indispensable link in the development of new medicines. As a neurologist and Head of the Neurology Department at Cliniques universitaires Saint-Luc, Professor Vincent van Pesch has been involved in numerous clinical trials for many years. As principal investigator, he draws on his expertise in multiple sclerosis to support patients participating in studies of innovative treatments and help develop new therapies. From his experience in the field, he sees how clinical research not only improves patients' quality of life but also makes an essential contribution to the advancement of medical science. In this interview, he shares his insights into the impact of clinical trials and the challenges researchers face today.

In conversation with Prof Chantal Mathieu (p.22)

Scientific progress and innovation rely on strong clinical research. Clinical trials provide doctors and researchers with new knowledge and give patients early access to innovative therapies. Belgium has considerable strengths: a strong hospital network, motivated research teams and well-informed patients. Professor Chantal Mathieu, Head of Endocrinology at UZ Leuven, explains why clinical research matters for our patients and for our scientific expertise, and why we must continue to build confidence in Belgium as a centre for research.

In conversation with Prof Wim Derave (p.29)

The human body is made to move. Yet our modern, often sedentary lifestyle causes health problems that go beyond cardiovascular disease. That is why Wim Derave, Professor of Exercise Physiology at Ghent University, has long advocated making physical activity an integral part of treatment. He warns against focusing too narrowly on how new medicines affect blood test results, without paying sufficient attention to their effects on sleep, nutrition and muscle mass. His message is clear: it is not a matter of either medication or exercise, but a combination of the two that offers the best chance of lasting health gains.

In conversation with Prof Bart De Strooper (p.34)

Following the approval of the first Alzheimer’s medicines, pharma.be spoke with VIB-KU Leuven molecular biologist Bart De Strooper. Alzheimer’s disease has long been an enigma and remains a taboo subject, as though it were an inevitable and irreversible consequence of ageing. But according to Bart De Strooper, that is a persistent misconception. He welcomes the first generation of treatments moving from the laboratory into patient care and compares this progress to the breakthrough in AIDS treatments in the 1980s. Greater awareness creates opportunities for early intervention. All the parties involved must now work together to give patients timely access to this care.

In conversation with Prof Martine Piccart (p.45)

How has biopharmaceutical innovation transformed breast cancer treatment? Which advances make the greatest difference to patients today? And how can we ensure that new therapies remain accessible in the future? Professor Martine Piccart, medical oncologist and Scientific Director of the Institut Jules Bordet, reflects on major breakthroughs, discusses the remaining challenges and looks ahead to a promising future in which the right treatment must reach the right patient.

In conversation with Niko Deyaert (p.104)

Humans and animals share the same planet, but how do medicines for the two groups relate to each other? Niko Deyaert, Country Manager for Benelux at Huvepharma, has witnessed significant developments in veterinary medicine. He attributes this progress primarily to a broader understanding of the relationship between animals, those who care for them and their environment, supported by closer collaboration among all stakeholders. The One Health concept, which connects human, animal and environmental health, is also gaining importance, although he cautions against generalisations. At the same time, he is concerned about the limited development of new therapeutic molecules, despite major innovations in vaccination.

In conversation with Frank Lorré and Isabelle De Walsche (p.123)

How can a smaller pharmaceutical company make a difference in a sector dominated by large multinationals? According to Frank Lorré, Market Access & Public Affairs Director for Belux at Ipsen, and Isabelle De Walsche, Managing Director at Gedeon Richter Benelux, smaller companies draw their strength from their agility and local roots. This enables them to meet the needs of patients with rare diseases, which often receive less attention from larger companies. Yet this also presents significant challenges: biopharmaceutical innovation requires substantial research funding, while treatments often serve small patient populations.

Become a member

Schrijf je in op onze nieuwsbrief

Wil je op de hoogte blijven van het reilen en zeilen binnen de farma-industrie, schrijf je dan in op onze nieuwsbrief!